The Zacks Analyst Blog Abbott, BlackRock, ConocoPhillips, NetSol and Optex Systems

In This Article:

For Immediate Releases

Chicago, IL – November 29, 2024 – Zacks.com announces the list of stocks and featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include including Abbott Laboratories ABT, BlackRock, Inc. BLK and ConocoPhillips COP, NetSol Technologies, Inc. NTWK and Optex Systems Holdings, Inc OPXS.

Here are highlights from Friday’s Analyst Blog:

Top Research Reports for Abbott, BlackRock and ConocoPhillips

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, BlackRock, Inc. and ConocoPhillips, as well as two micro-cap stocks, NetSol Technologies, Inc. and Optex Systems Holdings, Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Abbott shares have outperformed the Zacks Medical sector (+7.2% vs. +0.5%) this year, but have lagged the S&P 500 index over the same time period (+7.2% vs. +26.5%).

The Zacks analyst believes that Alinity, the company’s next-generation suite of systems, is a key driver in the core lab diagnostics business. EPD's impressive performance stems from the company’s unique business model. Freestyle Libre CGM device is also on a great trajectory. Within Nutrition, despite softness in the global pediatric arm, Abbott is regaining market share banking on strong Adult Nutrition business.

However, the significant runoff of COVID-19 testing-related sales is hurting Abbott’s Diagnostics growth. Tough macro conditions also remain a headwind.

(You can read the full research report on Abbott here >>>)

BlackRock shares have underperformed the Zacks Financial - Investment Managementindustry over the past year (+39.3% vs. +59.7%). The Zacks analyst believes that high operating expenses have been hurting BlackRock’s profitability. Its reliance on overseas revenues exposes it to geopolitical tensions, different regulatory/economic environments and exchange rate fluctuation.

Yet, efforts to restructure active equity business and strengthen private markets capabilities are expected to support top-line growth. The planned acquisition of Preqin, along with the buyouts of Global Infrastructure Partners and a stake in SpiderRock, should also aid.

(You can read the full research report on BlackRock here >>>)